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Abstract 
 
Lysosomal storage disorders (LSD) are caused by lysosomal dysfunction usually as a 
consequence of deficiency of a single enzyme required for the metabolism of macromolecules 
such as lipids, glycoproteins and mucopolysaccharides. For instance, the lack of α-
Galactosidase A (GLA) activity in Fabry disease patients causes the accumulation of 
glycosphingolipids in the vasculature leading to multiple organ pathology. Enzyme 
replacement therapy (ERT), which is the most common treatment of LSD, exhibits several 
drawbacks mainly related to the instability and low efficacy of the exogenously administered 
therapeutic enzyme. In this work, the unprecedented increased enzymatic activity and 
intracellular penetration achieved by the association of a human recombinant GLA to 
nanoliposomes functionalized with RGD peptides is reported. Moreover, these new GLA 
loaded nanoliposomes lead to a higher efficacy in the reduction of the GLA substrate named 
globotriasylceramide (Gb3) in a cellular model of Fabry disease, than that achieved by the 
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same concentration of the free enzyme. The preparation of these new liposomal formulations 
by DELOS-SUSP, based on the Depressurization of a CO2-Expanded Liquid Organic 
Solution, shows the great potential of this CO2-based methodology for the one-step 
production of protein-nanoliposome conjugates as bioactive nanomaterials with therapeutic 
interest. 
1. Introduction 
Fabry disease is an inherited failure of the glycosphingolipid metabolism due to a deficient 
lysosomal α-galactosidase A (GLA) activity.[1,2] This enzymatic deficiency causes 
progressive accumulation of the glycosphingolipid, globotriaosylceramide (Gb3), in vascular 
endothelial lysosomes of kidneys, heart, skin and brain leading to multi-systemic clinical 
symptoms.[3,4] First clinical signs occur during childhood and, over time, microvascular 
disease of the affected organs progresses leading to early death.[5] Vasculature is directly 
involved in the pathophysiology and progression of the Fabry disease[6] Indeed, endothelial 
cells are the most predominantly affected cell type in this disease [5] and targeting of 
endothelial cells seems to be reasonable approach to improve the treatment and life-
expectancy of Fabry patients.[7] The current treatment, available since 2001, is the enzyme 
replacement therapy (ERT) in which a recombinant protein is administered intravenously to 
patients every other week. Two of such treatments are currently commercialized: agalsidase 
alfa (Replagal®; Shire Human Genetic Therapies, Dublin, Ireland) and agalsidase beta 
(Fabrazyme®; Genzyme Corporation, Cambridge, MA). Another chemically modified 
version of the recombinant α-galactosidase A protein is currently being tested in phase I/II 
clinical trials (PRX-102; Protalix Biotherapeutics, Carmiel, Israel)[8]. GLA enzyme 
replacement therapy has demonstrated positive effects on clearing Gb3 from plasma and the 
target organs, reversing the pathogenesis of the disease.[9,10] However, this approach presents 
some disadvantages related to: a) its limited efficacy in patients with an advanced stage of the 
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disease, b) short half-life of the enzyme mainly due to the sequestration of the enzyme by the 
liver, and c) the high cost of the treatment (280.000 €/patient·year) due to the need for 
repeated administration of large amounts of enzyme.[4,11,12] For this reason, new treatment 
strategies are nowadays under investigation. For instance, in PRX-102, currently in clinical 
trials, GLA enzyme has been chemically modified with a homo-bifunctional polyethylene 
glycol (PEG, 2000 Da) cross-linker attached to the two protein subunits of the GLA enzyme, 
resulting in a PEGylated and covalently bound homo-dimer. This chemical modification of 
the enzyme, produced in a tobacco plant cell culture, is equivalent in functionality to the 
mammalian produced GLA, but vastly improves serum-half life as well as plasma and 
lysosomal stability. Gene therapy, chaperons or substrate reduction, constitute alternative 
therapies to ERT, which are at present under investigation [13-16]. The use of drug delivery 
systems represents a promising opportunity to enhance the efficacy of ERT. In this sense, 
nanotechnology offers a great availability of materials and strategies to build up the “perfect” 
nanocarrier for the precise and targeted delivery of therapeutic biomolecules, such as GLA 
used in ERT for Fabry disease. In this approach, in which the biomolecule is not chemically 
modified, the efficacy improvement is attained through its non-covalent assembling to a  
nanocarrier. For example, Giannotti et al. reported the formation of stable polyelectrolyte 
complexes between trimethyl chitosan and GLA, and their traffic to lysosomal compartments 
of human endothelial cells.[11] Polymeric nanoparticles coated with anti-ICAM-1 (an antibody 
expressed on endothelial cells and cells of the immune system) and loaded with GLA have 
also shown an increased endocytosis of the carrier by vascular endothelial cells as well as Gb3 
degradation.[17] Unfortunately most of these systems are metastable and tend to lose their 
colloidal stability with time.[18] Moreover, their physicochemical parameters change upon 
interaction with complex systems, such as the physiological media preventing their 
intravenous dosage, but also with the intracellular environment, which can affect the 
performance of the drug.[19,20] Therefore, critical parameters such as chemical composition, 
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size, geometry, charge, stability over time and loading efficiency need to be carefully 
controlled and fixed during the preparation of GLA nanoconjugates. This is particularly 
crucial in order to establish a correlation between the structure of the nanocarrier and its 
biological effectiveness. Changes in the structuring of the carrier upon loading of the cargo 
molecule and/or upon formation of the protein corona have shown to directly affect cell 
internalization patterns and thus the efficiency of drug/enzyme release and its 
bioavailability.[21-23]  
Recently, we have demonstrated the potential of the DELOS-SUSP method for the easy and 
direct preparation of different vesicle-biomolecule conjugates with nanoscopic size and great 
degree of unilamellarity.[24,25] This methodology, based on the use of compressed CO2, shows 
a high “batch-to-batch” consistency allowing for the preparation of sufficient quantities (up to 
liter scale) of nanotherapeutics for clinical testing. Importantly, the bioactivity of the 
integrated molecules is unaffected under the mild processing conditions and their scale-up 
production is possible following GMP (Good Manufacturing Practices) requirements. 
Although liposomes, and in general lipid-based vesicles, are well recognized as useful and 
versatile drug carriers,[26-28] there is no previous reference of their use in the 
integration/encapsulation of GLA for the ERT of Fabry disease. In this work we present a 
new promising liposomal nanomedicine candidate, capable of specific targeted delivery of the 
GLA enzyme to the lysosomes of endothelial cells. In this nanomedicine, GLA is conjugated 
to liposomes functionalized with a RGD targeting peptide.[25] On the one hand, the 
incorporation of this endothelial cell targeting peptide stabilizes the final liposomal 
formulation .[25,29] On the other hand, the RGD moiety allows for αvβ3 integrin recognition, 
expressed in vascular endothelial cells,[30] which could promote a more specific and effective 
cellular uptake . Indeed, the use of receptor mediated internalization of the enzyme has been 
already described for the treatment of LSD either using chimeric proteins where the lysosomal 
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enzyme has been fused to Tat or IGF II proteins,.[31] or in nanoparticles where targeted 
delivery was mediated by anti ICAM-1 antibodies .[17] As explained above, the targeting of 
the nanovesicles to the vascular endothelial cells is not spurious, since alterations in the 
vasculature are thought to be crucial in the pathophysiology of Fabry disease.[6] Moreover, the 
αvβ3 integrin expression and urinary excretion has been already linked to the progression of 
the renal injury in Fabry disease.[32] Therefore, we envision that the use of RGD decorated 
liposomes carrying GLA would improve the efficacy of the current enzyme replacement 
therapy.  
2. Results and Discussion 
2.1. Preparation and Physicochemical Characterization of Nanoconjugates 
2.1.1. Preparation 
The recombinant human GLA used for the preparation of the conjugates was obtained by a 
transient gene expression-based production method[33] (SI, Section 2). “Compared to the 
clinically approved versions of the GLA, our GLA contains an HIS-tag that permits its rapid 
an efficient purification, retaining 70% of the enzymatic activity of the clinically available 
proteins. Moreover, the use of this “in-house” version of GLA allowed us to control the buffer 
and media in which the enzyme is contained. Such additives are not quantitatively described 
for the clinical versions (Replagal and Fabrazyme) and therefore their potential effect in the 
encapsulation of the protein cannot be excluded.” 
The enzyme loaded nanovesicles were prepared following the procedure schematically 
represented in Figure 1 and described in Methods. Briefly, an ethanolic solution containing 
cholesterol, 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and RGD peptide linked 
to cholesterol (cholesterol-PEG200-RGD) in a molar ratio 6:10:1 was added to a small-scale 
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reactor of 7.5 mL and pressurized with large amount of compressed CO2. The nanoconjugates 
were formed by depressurizing the resulting CO2-expanded solution of lipids over an aqueous 
solution containing the GLA enzyme at the desired concentration. Three different enzyme 
concentrations, 8.5, 20.0 and 42.5 µg mL-1, were tested for the preparation of the liposomal 
systems. No further energy input was required for achieving the desired structural 
characteristics of GLA loaded liposome-RGD conjugates, neither for increasing the loading or 
the integration efficiencies. The composition of the organic and aqueous phases used for the 
preparation of the different GLA liposomal conjugates are given in the Table S1 (SI, Section 
3). The reasons for using the RGD peptide were two: a) Cells affected by the Fabry disease 
show over-expression of integrins, which are ligands for RGD and b) to take advantage of the 
integrin internalization pathway for the uptake of the nanoconjugates.[25] 
2.1.2. Physicochemical Characterization 
The particle size, polydispersity index (PdI) and ζ-potential of the resulting nanoconjugates 
were determined using a dynamic light scattering (DLS) equipment and are reported in 
Table 1. Although all the conjugates were in the nano-scale range, their average sizes (168, 
216 and 226 nm) and polydispersity were influenced by the GLA concentration in the 
liposomal system (8.5, 20.0, and 42.5 µg mL-1). Thus, the higher the enzyme concentration 
the larger the particle size. In addition, ζ-Potential values, which are indicators of the colloidal 
stability, showed a dependence on the enzyme concentration. In theory, higher ζ-potential 
values, being positive or negative, tend to stabilize colloidal systems. Usually particle 
aggregation is less likely to occur for charged particles with pronounced ζ-potential values 
due to the electrostatic repulsion between particles with the same electrical charge. 
Accordingly, systems containing 8.5 µg mL-1 of the enzyme showed the highest ζ-potential 
value (+18.0 mV) and were stable for at least two months (See SI, Section 4.1), whereas 
liposomal systems with 42.5 µg mL-1 and with the lowest ζ-potential value (+9.4 mV), 
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presented a slight phase separation within the first 15 days after their preparation.  
Nevertheless, after a diafiltration procedure to separate the non-loaded enzyme from the 
aqueous dispersion of GLA loaded nanoliposomes, all the ζ-potential values changed from 
positive to negative (≤-25 mV), explaining the increase in stability observed. 
These results indicate that there is a tendency towards less homogeneous and less stable 
liposomal systems when increasing the enzymatic concentration. This behavior was observed 
not only when the dispersant medium was pure mQ water, but also in physiological media, 
such as several physiological buffers or even in cell culture media, which is a water-based 
solution containing mainly serum proteins and with a relatively high ionic strength (See SI, 
Section 4.2). The composition of the vesicular membrane of all nanoconjugates described in 
Table 1 is exactly the same; therefore we can conclude that the incorporation of the cargo 
molecule, the GLA enzyme, is the main reason for the alteration of the nanocarrier’s structure 
and thus, their physicochemical properties. Next, we quantified the amount of incorporated 
enzyme in the GLA loaded liposome-RGD conjugates. For this, the non-loaded GLA was 
separated from the loaded vesicles by a diafiltration process (SI, Section 5). The total sample 
and the loaded vesicles were analyzed by SDS-PAGE and further Western-blot and the 
entrapment efficiency (EE) was calculated dividing the mass of integrated enzyme by the total 
initial mass used in the experiment (Table 1). EE values of c.a. 40±10% were obtained in all 
cases. Hence, liposomal systems free of non-conjugated enzyme with 3, 7, and 16 µg mL-1 of 
GLA concentration, were obtained respectively by diafiltration of the original liposomal 
systems with 8.5, 20.0 and 42.5 µg mL-1 of GLA concentration. As it can be seen in Table 1, 
GLA loading of nanoconjugates increases with the increase of GLA concentration of the 
liposomal system. Even when the enzyme loadings were not very high, the effectiveness of 
the integrated GLA was improved compared to the free enzyme as we will show below.  As 
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detailed in the Supporting Information, the loaded nanoconjugates were able to retain 84% of 
the initial encapsulated GLA after 21 days stored at 4 ºC (SI, Section 6).  
Finally, for liposomal system free of non-conjugated enzyme with a 7 µg mL-1 of GLA 
concentration, we estimated the ratio between GLA adsorbed on the outside surface of the 
liposomes and GLA encapsulated in the liposome. To do this estimation, a new sample, 
named as  “Liposome-RGD + Free GLA + Diafiltration”, was prepared by incubating empty 
liposomes-RGD (see Table S1 of SI) with free GLA at a concentration of 20 µg mL-1 during 
24h, followed by a diafiltration process to take out the GLA non-adsorbed on the bilayer.  
SDS-PAGE and further Western-blot analysis (Methods) revealed that this sample has a GLA 
concentration of 3.5 ± 0.8 µg mL-1. Theoretical MD simulations, reported later on in this 
paper, show that GLA is incorporated in the membrane as a peripheral protein. Therefore, it is 
worthy to suppose that all GLA of this new liposomal system is adsorbed on the outside 
surface of the bilayer and that no entrapped GLA is present. By the comparison of the above 
described liposomal systems, a ratio of “GLA adsorbed/GLA encapsulated” close to 1 can be 
estimated for the liposomal system free of non-conjugated enzyme with a 7 µg mL-1 of GLA 
concentration. 
Figure 2 clearly shows how the amount of loaded enzyme influences the final morphology of 
the nanoconjugates. When there is no protein load, spherical and unilamellar vesicles are 
observed by direct inspection with cryo-TEM and by averaged structural characterization with 
SAXS (See SI, Section 15.3). This morphology changes towards more polydisperse 
oligolamellar systems with GLA loading. At 16 µg mL-1 GLA concentration, the increase in 
broadness of the SAXS curve indicates a higher polydispersion in the interbilayer distance in 
comparison to less GLA loaded nanoconjugates. Indeed it is described that biomolecules may 
induce phase transformations, free energy releases, restructuring and dissolution at the 
nanomaterial surfaces.[34] 
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2.1.3. Specific Enzymatic Activity of Free vs. Conjugated GLA 
The preservation of the specific enzymatic activity of GLA, which is the enzyme activity per 
milligram of total enzyme, after the entrapment process was subsequently measured 
(Methods). To this end, free and conjugated GLA were incubated with a non-fluorescent 
substrate (4-MUG) that after GLA cleavage renders a fluorescent product (4-MU). By 
measuring the increase of the fluorescence signal upon enzymatic hydrolysis of the substrate, 
we could establish the specific activity of GLA in its different forms. As it could be observed 
in Table 2, unloaded liposome-RGD do not give any fluorescence signal, showing that these 
liposomal carriers do not affect the enzymatic assay.   We studied the three following samples 
for comparison: (i) free GLA in water withdrawn from the aqueous phase used in the 
experiments, (ii) GLA loaded liposomes obtained after the diafiltration process, and (iii) total 
GLA, corresponding to the fraction prior diafiltration in which the non-loaded and the 
liposome-integrated GLA coexist together. Table 2 shows the specific enzymatic activity 
values for such samples. Remarkably, the specific activity of the GLA always increases when 
it is conjugated to the liposomes. In the liposomal systems with 8.5 and 20 µg mL-1 GLA 
concentrations, it was observed a significant specific activity increase when non-conjugated 
GLA was separated by diafiltration. Figure 3A shows the ratio between the specific 
enzymatic activities of the GLA loaded nanoconjugates and of the free GLA. The increment 
in the specific activity is 3-fold for the nanoconjugates with 3 and 7 µg mL-1 GLA 
concentration, but reduces to 1.3-fold for the conjugate with 16 µg mL-1 GLA content. To the 
best of our knowledge, such increase of the activity of the enzyme after its conjugation to 
liposomes has not been observed before.  
In order to discard the influence of CO2 or ethanol in this activity enhancement, the specific 
activity of GLA was also measured in a sample obtained by depressurizing CO2-expanded 
ethanol free of lipids over a water solution containing the enzyme at concentration of 
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8.5 µg mL-1. The resulting specific activity was similar to that obtained for the GLA in water 
without any treatment. This result indicates that the activity enhancement is related to the 
enzyme-liposome association (SI, Section 7). A similar increment in specific activity for GLA 
was recently reported by Corchero et al. when GLA was immobilized on the surface of 
magnetic particles.[35] This enhancement was related to the covalent anchoring of the enzyme 
with a “site-specific” oriented manner. This explanation could also apply for our liposomes, 
since the GLA may be interacting directly with the lipid bilayer immobilizing the enzyme. 
Indeed, immunomicroscopy images show the presence of the enzyme in the membrane of 
nanovesicles (see SI, Section 8). Although GLA is not covalently bound, other kind of 
interactions (i.e. electrostatic and/or hydrophobic) between the enzyme and the lipid 
membrane components may ensure enzyme immobilization. This in turn might be responsible 
for the increased activity. Other examples of enhanced enzymatic activity with nanoparticle-
bioconjugates, mainly using inorganic nanoparticles, have also been discussed by Brandy J. 
Johnson et al., when compared to freely diffusing enzyme in bulk solution. [36] 
In order to confirm our hypothesis, we performed a theoretical analysis, with atomistic 
resolution, of the interaction of the GLA protein with the bilayer. Our modeling of the protein 
employs the X-ray structure determined by Garman et al.[37]. The analysis was made using 
two different techniques, the thermodynamic technique described by Lomize et al.[38] and 
large-scale atomic molecular dynamics simulations.  
First, we determined the preferred orientation and positioning of the protein, relative to a 
bilayer, using the fast and accurate thermodynamic methodology described in Lomize et 
al.[38]. We obtained that GLA dimer is incorporated as a periphelical protein, with only eight 
residues of a single monomer embedded in the bilayer and an overall tilt angle of 70 ±10o 
(Figure 4). These residues are LYS374, GLY375, VAL376, ASN379, PRO380, TRP399, 
THR400, MET421, which are located  in the second domain of the monomer. The active site 
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of the protein is found in the first domain (see Figure 2 in Garman et al.[37]), at about 2.6 nm 
from the bilayer. The free energy of transfer estimated from the thermodynamic method is -6 
kcal mol-1. 
Although in general the thermodynamic calculation is accurate for protein-bilayer 
interactions[38], it has limitations. In particular, it considers the full structural detail of the 
protein but considers only implicitly the solvent (water) and the membrane. In fact, the model 
for the membrane is so generic that the composition of the bilayer is neglected.  In order to 
refine our calculations, we have confirmed the results of the simplified thermodynamic model 
by performing large-scale molecular dynamics simulations under conditions of 1 atm, 25 ºC 
and pH=7. In our simulations, we considered the interaction of GLA with a fully hydrated 
membrane patch containing DPPC and cholesterol with a 10:6 molar ratio, representative of 
the experimental situation.  Since our previous thermodynamic calculation shows that only 
one monomer of the dimer interacts with the bilayer, we have performed our simulations 
considering only one monomer of the protein. In spite of this simplification, the simulation 
box contains more than 105 atoms, a substantial amount which requires the use of 
supercomputing facilities. Full technical details of the simulations are given in the Supporting 
Information (SI, Section 16). 
The results obtained from the MD simulations confirm that only the residues identified by the 
thermodynamic method (located in the second domain) are responsible for the interaction 
with the DPPC/Cholesterol bilayer, so the active center is located far from the membrane. In 
our MD simulations these residues do not fully penetrate inside the bilayer. Rather, they are 
typically surrounded by choline lipid head groups. We do not observe direct binding between 
atoms of these protein residues and atoms in the DPPC lipids (hydrogen bonds or other). In 
fact, the distance between closest protein and DPPC atoms is always larger than 0.25 nm. It 
has to be emphasized also that positioning of the protein at the membrane does not alter its 
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structural features. The RMSD of the protein during the trajectory is only 1 Å taking as a 
reference structure the initial (unbound) protein.  
Overall, our calculations suggest that the GLA protein is incorporated onto the nanocarriers 
adsorbing its second domain at the bilayer surface, as a peripheral protein, without 
modification of its structure. The adsorbed protein has its first domain oriented with the active 
site exposed towards the aqueous phase (opposite to the bilayer). This particular orientation of 
the immobilized protein, which is favorable for the protein enzymatic activity, also suggests 
that its adsorption at a surface can lead to an increased activity, as observed experimentally.  
Additionally, the theoretical results described above could also explain the smaller specific 
activity increase observed for the conjugates with the highest GLA loading (Figure 3A). 
Indeed, less loaded liposomes showed a more homogeneous morphology regarding size and 
interbilayer distance. On the contrary, nanoconjugates with a higher loading (16 µg mL-1 in 
GLA concentration) showed a higher morphological polydispersity. The increase in 
oligolamellarity and polydispersion reduce access of the enzyme to the media, hindering its 
availability to metabolize the substrate and explaining its lower performance. Certainly, this 
issue requires and deserves further and deeper analysis. Nevertheless two phenomena 
appeared to have a decisive role in the observed increased activity upon integration: firstly a 
possible immobilization of the enzyme at the lipid bilayer and secondly, the availability of the 
enzyme to the substrate due to a more homogeneous and unilamellar vesicle structures.   
The stability of the entrapped GLA enzyme, during a 4 weeks period, was further studied by 
measuring the specific activity in samples with free and entrapped GLA, corresponding to the 
liposomal system with initial GLA concentration of 8.5 µg mL-1 (Figure 3B). Neither the 
activity of the free GLA in water nor the activity of the enzyme associated to the liposomes 
was affected after one month. Although no differences in stability were found between the 
free and the encapsulated enzyme along time, a higher specific activity was present in the 
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fractions in which the GLA was associated to vesicles compared to the free enzyme and 
remained unchanged during the 4 weeks. The specific activity was also measured after 14 
weeks in samples were the enzyme was associated to the liposomes -both in samples without 
non-loaded enzyme and with it- and around 70% of the initial activity still remained in the 
formulation (SI, Section 9).  
2.1.4. Biological Characterization of  Nanoconjugates 
Cytotoxicity, Hemocompatibility, and Sterility Assays: For the biological characterization of 
nanoconjugates we selected the less loaded RGD-functionalized liposomes (i.e. with 3 µg mL-
1 of GLA) due to their superior colloidal stability. Such experiments were carried out on with 
HeLa (cervix adenocarcinoma) and HMEC-1 cells (human microvascular endothelial cell line, 
obtained from Centers for Disease Control and Prevention/National Center for Infectious 
Diseases (CDC-NIDR)). Both types of cells were incubated with plain liposomes (non RGD 
functionalized liposomes), unloaded liposomes-RGD and with GLA loaded liposomes-RGD. 
Cell viability of both cell lines was not affected after 72 h (SI, Section 10) showing the lack of 
cytotoxicity of nanoconjugates in the range of concentrations tested. The three kinds of 
liposomes were also non-hemolytic, presenting a hemolytic percentage always under 2% (SI, 
Section 11), and sterile (SI, Section 12).  
Cellular Internalization: Functionalization of colloids with RGD peptides is a common 
strategy to facilitate/accelerate their internalization by cells via integrin receptors 
recognition.[39-41] In our previous work, we demonstrated that liposomes-RGD, with the same 
membrane lipid composition used in the present work, showed 30-fold higher uptake by 
HMEC-1 cells than plain liposomes not functionalized with RGD, but with a similar 
cholesterol:DPPC molar ratio, the same DPPC concentration and prepared following the same 
CO2-based procedure.[25] Here we studied the internalization of RGD-functionalized 
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nanoliposomes loaded with GLA at two different enzyme concentrations (i.e. 3 and 7 µg mL-
1) in order to see if the slight differences in the chemical structuring of the nanocarriers could 
interfere with their uptake by living cells. As controls, GLA loaded plain liposomes at the 
enzyme concentration of 7 µg mL-1, as well as unloaded liposomes with and without RGD 
functionalization were also evaluated. For the flow cytometry assays, HMEC-1 cells (known 
to overexpress αvβ3 integrins necessary for RGD targeting)[30] were incubated for 30 and 180 
minutes at 16 and 37 ºC with 0.3 mg mL-1 DiD-labeled liposomes (plain liposomes, GLA 
loaded plain liposomes, unloaded liposomes-RGD and GLA-loaded liposomes-RGD with the 
two aforementioned enzyme concentrations). In agreement with our previous data,[25] results 
reflected that cellular uptake of the liposomes was enhanced with the presence of the RGD, 
regardless the presence of the GLA. Moreover, as it is clearly observed in Figure 5 the 
internalization is not significantly affected by the different GLA loading of liposomes-RGD.  
Indeed, unloaded liposomes-RGD and GLA loaded liposomes-RGD at two different enzyme 
concentrations (i.e. 3 and 7 µg mL-1), show the same internalization rate at 180 min at 37ºC, 
regardless that the  number of GLA's per nanoliposome is 0, 1 and 3 respectively (see Table 
1). 
As it can be observed in Figure 5, after 180 minutes of incubation, 38±1 % of the cells 
exhibited internalization of DiD-labeled liposome-RGD conjugates at 37 ºC, whereas this 
percentage was kept at 6±2 % for cells incubated with unloaded and GLA-loaded DiD-labeled 
plain liposomes, without RGD targeting. Furthermore, a decrease in the fraction of positive 
cells was observed for all the formulations when cells were incubated with the DiD-labeled 
samples at 16 ºC, a temperature that reduces the endocytosis and, thus, allows determining the 
percentage of vesicles that bind to the cell membrane nonspecifically (Figure 5 A). When the 
mean fluorescence intensity (MFI) associated to the cells that have internalized the DiD-
labeled liposomes was quantified (Methods), significantly higher MFI values were obtained 
 17 
 
for the cells incubated with DiD-labeled liposome-RGD conjugates (Figure 5 B). Although 
initially the internalization kinetics of the GLA-loaded liposomes-RGD conjugates was 
slower when the enzyme loading was higher, after 180 minutes the uptake of both systems 
was almost the same. 
The results were also confirmed by laser scanning confocal microscopy (LCSM).  For this 
assay, HMEC-1 cells were incubated for 180 minutes at 37 ºC, to induce internalization, with 
0.3 mg mL-1 DiD labelled liposomes, and stained with Lysotracker Green (Methods and SI, 
Section 13). Confocal images depicted that all RGD-functionalized liposomes (loaded or 
unloaded) had already entered the cells after 180 minutes incubation and were localized 
within lysosomes (Figure 6).  Therefore, this strategy ensures the release of the cargo at the 
right target organelle via RGD-integrin binding. Other alternative targeting moieties such as 
Tat peptide, IGF-II or anti-ICAM-1 have been described as a way to improve the 
biodistribution of the therapeutic enzyme, and in turn, increase the overall efficacy of 
ERT.[16,42,43] 
In Vitro Enzymatic Efficacy: The ability of the GLA delivered by the liposome-RGD 
conjugates to reduce Gb3 deposits was tested in a cellular model of Fabry disease. To this 
end, GLA knock out (KO) mouse aortic endothelial cells (MAEC) were cultured and the 
capacity of different GLA loaded liposome-RGD conjugates formulations to metabolize its 
substrate (Gb3) was investigated by means of flow cytometry (Methods). MAECs have been 
described to overexpress αvβ3 integrins.[30] Figure 7 shows the effect in the Gb3 loss for the 
formulations containing: a) free GLA in water, b) GLA loaded liposome-RGD conjugates 
plus non-loaded GLA (Total GLA), and c) only GLA loaded liposome-RGD conjugates 
(Loaded GLA), corresponding to liposomal system with initial GLA concentration of 20 µg 
mL-1 (Table 1). The latter two samples produced a Gb3 loss better than the free enzyme, a 
result which is in agreement with the higher specific activity measured for these samples.  
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This result was attributed to the conjugation of GLA to the nanoliposomes, since as depicted 
in Figure 7, empty liposome-RGD did not show any capacity to reduce Gb3 deposits. 
In order to shed some light on the understanding of why the combination of free enzyme and 
liposome-loaded GLA (Total GLA) has a considerably better performance reducing 
lysosomal Gb3 deposits than formulation containing only GLA loaded liposomes free of non-
loaded enzyme (Loaded GLA), the capacity of two additional liposomal systems to clear Gb3 
was also investigated. Formulation named as “Loaded GLA+Free GLA” was prepared by 
mixing the sample labeled as “Loaded GLA” (free of unloaded enzyme and with an enzyme 
concentration of 7 µg mL-1) with additional GLA to reach a GLA sample concentration of 
20 µg mL-1, equal to the GLA concentration of sample labeled as “Total GLA”. Formulation 
labeled as “Liposome-RGD + Free GLA + Diafiltration”, described before in 
Physicochemical characterization Section, has all GLA adsorbed on the outside surface of the 
bilayer and no GLA protein is present inside the nanoliposome. As it can be observed in 
Figure 7, the sample “Loaded GLA+free GLA”, which was prepared to artificially 
reproduce the “Total GLA” sample, shows exactly the same capacity to clear Gb3. This result 
confirms that the coexistence of GLA loaded liposomes with the free enzyme gives a better 
Gb3 clearance than GLA loaded liposomes alone (sample “Loaded GLA”).  
These results could be explained if it is recognized that we can distinguish among three 
different types of GLA: a) Free GLA in water; b) GLA immobilized on the outside surface of 
the liposome bilayer, and according to theoretical simulations, anchored with a “site-specific” 
orientation with the active site exposed to the aqueous phase (opposite to the bilayer) and c) 
GLA encapsulated inside the nanoliposome with a reduced access to the media. According to 
their accessibility to the media, it is probable that the ability to metabolize Gb3 of the three 
types of GLA decreases from the first one to the third one. Assuming this analysis, the results 
depicted in Figure 7 can be easily understood. Indeed, sample “Liposome-RGD+Free 
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GLA+diafiltration” contains only the most accessible GLA, which is the one adsorbed on the 
outside surface of the liposomes, explaining its higher ability to reduce Gb3 deposits, with a 
mean GLA concentration value to reduce Gb3 deposits to the 50% (IC50) of 0.062 ± 
0.004 μmol h-1 mg-1. Samples labeled as “Total GLA” and “Loaded GLA + Free GLA”, have 
the same composition with the three types of GLA. It explains their equal capacity to clear 
Gb3 (IC50 = 0.078 ± 0.005 and IC50 = 0.078 ± 0.009 μmol h-1 mg-1, respectively) and their 
slightly lower capacity to reduce Gb3 in comparison to the previous formulation, which 
contains only the most accessible GLA. Sample labeled as “Loaded GLA”, is composed of 
the same amount of GLA adsorbed on the outside membrane of the liposomes and of GLA 
entrapped inside the liposomes, as the sample “Total GLA”, but on the contrary, this sample 
is free of non-loaded GLA, which is expected to have a higher ability to metabolize Gb3 than 
the entrapped one. This explains why “Loaded GLA” has a lower capacity to reduce Gb3 
(IC50 = 0.14 ± 0.01 μmol h-1 mg-1) than “Total GLA”. Finally, the slightly higher capacity to 
clear Gb3 of “Loaded GLA” than the free enzyme “GLA” can be explained by a much higher 
ability to clear Gb3 of GLA adsorbed on the outside membrane (sample “liposome-
RGD+Free GLA+diafiltration”, IC50 = 0.062 ± 0.004 μmol h-1 mg-1) in comparison to the 
free enzyme (“GLA”, IC50 = 0.19 ± 0.03 μmol h-1 mg-1), which might compensate the effect 
of having a portion of the less active entrapped GLA in sample “Loaded GLA”. 
3. Conclusion 
Multifunctional nanoconjugates, composed by liposomes functionalized with RGD peptides 
and encapsulating GLA, were successfully prepared using the DELOS-SUSP method. This 
methodology yields nanometric conjugates with entrapment efficiencies around 40% that 
were non-cytotoxic, non-hemolytic and sterile. In vitro behavior of the GLA nanoconjugates 
has shown to be extremely related to its physicochemical characteristics and morphology. 
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This result confirms the great importance of controlling nanostructure and physicochemical 
properties of drug delivery system, such as liposomal formulations. [44] 
Specific enzymatic activity assays performed on GLA conjugates showed a significant 
increase in the values reported when the enzyme was conjugated to the nanoliposomes in 
comparison with the values obtained for free GLA. In vitro activity studies in GLA deficient 
cells showed that the GLA loaded conjugates were also able to reduce lysosomal Gb3 
deposits more efficiently than the free enzyme, in agreement with the greater specific activity 
encountered. The reduction in the lysosomal accumulation of Gb3 indicates that i) 
multifunctional liposomes are uptaken by GLA deficient cells, ii) that such liposomes reach 
the lysosomal compartment and iii) that the cargo (GLA) is efficiently released so that the 
GLA activity in the cells is restored. Thus, GLA loaded liposome-RGD conjugates constitute 
a potential nanomedicine for improving the enzymatic replacement therapy in Fabry 
disease.[29] by increasing the endothelial targeting and the final efficacy of the recombinant 
enzyme. 
4. Experimental Section  
DELOS-SUSP Methodology for the Preparation of Nanoconjugates: For the nanoconjugates 
preparation, 1.2 mL of an ethanolic solution containing cholesterol, DPPC and cholesterol-
PEG200-RGD at a molar ratio 6:10:1, was loaded into a 7.5 mL high-pressure vessel at 
atmospheric pressure and at the working temperature (Tw= 308 K). The solution was then 
volumetrically expanded with compressed CO2 until a molar fraction (XCO2) of 0.85 was 
achieved, reaching a working pressure (Pw) of 10 MPa. The system was kept at 308 K and 10 
MPa for approximately 1 hour to achieve a complete homogenization and to attain thermal 
equilibration. 20 minutes before the depressurization stage, the enzyme (kept all the time at -
20 0C) was leaved at room temperature until defrost. Once defrost, a given volume of this 
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solution was dissolved in 24 mL of mQ water to reach the desired enzyme concentration (8.5, 
20 or 42.5 µg mL-1). In order to form the nanoconjugates, the volumetric expanded organic 
phase was depressurized over the aqueous solution containing the GLA. In this step a flow of 
N2 at the working pressure is used as a plunger to push down the CO2-expanded solution from 
the vessel and to maintain a constant pressure of 10 MPa inside the vessel during 
depressurization. Average time per experiment was 2 hours and the resulting suspensions of 
nanoconjugates were stored at 4 °C until characterization. Details of the equipment 
configuration are given in SI, Section 14. The experimental conditions used for the 
preparation of the organic and aqueous phases of each formulation are given in Table S1 (SI, 
Section 3). The average sizes, polydispersivities (PdI) and Z potentials of all nanoconjugates 
were measured using a dynamic light scattering analyzer, the particle concentration was 
measured by nanoparticle tracking analysis, the morphology was studied by Cryo-TEM and 
the vesicular structure was probed by synchrotron Small and Wide-Angle X-ray Scattering 
(SWAXS). (See more details in SI, Section 15). 
The production and physicochemical characterization of the nanoconjugates have been 
performed by the platform of Production of Biomaterials and Nanomaterials of the ICTS 
“NANBIOSIS”, more specifically by the Biomaterial Processing and Nanostructuring Unit of 
the CIBER in Bioengineering, Biomaterials & Nanomedicne (CIBER-BBN)/ Jesús Usón 
Minimally Invasive Surgery Center (CCMIJU)) at the Institut de Ciència de Materials de 
Barcelona (ICMAB-CSIC). 
Determination of the Entrapment Efficiency Percentage and Loading: To estimate the 
incorporation of GLA into liposomes-RGD, samples containing free GLA in water, samples 
with non-loaded and entrapped enzyme (total) and samples with GLA loaded liposomes after 
diafiltration, were mixed with denaturing, loading buffer and analyzed by SDS-PAGE and 
Western-blot, that was further developed using a rabbit polyclonal anti-GLA serum (Santa 
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Cruz Biotechnology) and a goat anti-rabbit IgG HRP-conjugate (Bio-Rad Laboratories, Inc.) 
as a secondary antibody. Amounts of GLA within each of the three above mentioned samples 
were estimated by comparison with known amounts (usually ranging from 25 to 125 ng) of 
GLA, previously produced, purified, and quantified in-house. Samples to be quantitatively 
compared were run in the same gel and processed as a set. Densitometric analyses of the 
bands were performed with the Quantity One software (Bio-Rad Laboratories, Inc). 
Percentage of encapsulated GLA was obtained by dividing the amounts of enzyme found in 
the loaded vesicles by the amount found in the total sample. 
Specific Enzymatic Activity: GLA enzymatic activity was assayed fluorometrically as 
described by Desnick et al. with the modifications of Mayes et al.[45,46] Basically, it was 
assayed by using 4-Methylumbelliferyl α-D-galactopyranoside (4-MUG, M-7633 Sigma 
Chemical) as substrate, at a concentration of 2.46 mM in assay buffer (0.01 M acetic acid, pH 
4.5). A typical assay reaction mixture contains 100 µL of substrate and 25 µL of the sample. 
Enzymatic reactions took place in agitation (tubes placed in a rotator, set at a rotation speed of 
25 rpm), at 37 ºC for 1 h, and were stopped with 1.25 mL of 0.2 M glycine-NaOH buffer (pH 
10.4). The released product (4-methylumbelliferone or 4-MU) was determined by 
fluorescence measurement at 365 and 450 nm as excitation and emission wavelengths, 
respectively. Samples of commercial product 4-MU (M-1381, Sigma Chemical) ranging from 
5 to 500 ng mL-1 in 0.2 M glycine-NaOH buffer, pH 10.4, were used to obtain a calibration 
curve in order to transform fluorescence readings into product 4-MU concentration. 
Enzymatic activity and specific enzymatic activities are expressed as “ng 4-MU mL-1 h-1” and 
“µmol 4-MU mg-1 h-1”, respectively. 
Flow Cytometry: HMEC-1 cells were detached using trypsin and incubated with DiD-labeled 
liposomes or DiD-labeled liposome-RGD conjugates (0.3 mg mL-1) re-suspended into MCDB 
131 media supplemented with 10 mM L-glutamine for 30 and 180 minutes at 16 ºC or 37 ºC. 
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No significant toxicity was observed after this short-term incubation. Cells were subsequently 
washed twice with Dulbecco´s phosphate buffered saline (DPBS) solution and re-suspended 
in cell culturing medium before subjecting to fluorescence-activated cell sorting analysis. 
Data acquisition and analysis was performed using FACScan (Beckton-Dickinson) and BD 
FACSDiva software. At least 104 viable cells were evaluated in each experiment. 
Cellular Uptake of Nanoconjugates Assessed by Laser Scanning Confocal Microscopy 
(LSCM): HMEC-1 cells were seeded onto Fluorodish culture plates (World Precision 
Instruments, Sarasota, FL) at a density of 2×105 cells per plate and allowed to grow for 36-48 
hours. 50 μl of DiD-labeled liposomes or DiD-labeled liposome-RGD conjugates (1.5 mg mL-
1) were mixed with 200 μl MCDB 131 medium, added into the cells and incubated for 180 
minutes at 37 ºC in a humidified atmosphere with 5% CO2. Subsequently, cells were washed 
with serum-free MCDB 131 and incubated at 37 ºC for 5 minutes with Lysotracker Green 
DND-26 (50 nM, Molecular probes, Eugene, Oregon) to label the endosomal/lysosomal 
compartments. The nuclei in live cells were stained with Hoechst 33342 dye (Sigma). Cells 
were examined under an inverted Leica SP5 laser scanning confocal spectral microscope 
(Leica Microsystems Heidelberg GmbH, Mannheim, Germany) using a 60x1.42 NA oil 
immersion objective. To visualize two colours of fluorescence simultaneously, we used the 
514 nm line from Argon laser for Lysotracker green and the 630 nm line from a He-Ne laser 
for DiD. 
In vitro cell assays: Primary cultures of mouse aortic endothelial cells (MAEC) of GLA 
deficient mice (GlatmKul1) were isolated at the In vivo Experimentation Platform from CIBER-
BBN and Vall d’Hebron Institute of Research (VHIR) following procedures previously 
described[47]. Endothelial origin of isolated cells was confirmed by CD105 staining. For 
activity assays, cells in passages 2 to 5 were seeded in 24 well plates and maintained at 37 ºC 
and 5% of CO2. Twenty four hours after seeding 8 µM of NBD-Gb3 (Matreya) was added to 
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the cultures along with the specified concentrations of tested compounds (free GLA enzyme, 
GLA loaded liposomes-RGD, empty liposome-RGD, etc.). After 48 h incubation, cells were 
trypsinized and Gb3-NBD fluorescent signal was analyzed by flow cytometry (FacsCalibur, 
Beckton Dickinson) and FCS Express v4 software. To calculate the percentage of Gb3-NBD 
signal, fluorescent signal in control cells (without treatment) was established as 100% and the 
rest of the values were normalized accordingly. Since GLA activity reduces those Gb3 
deposits, the percentage of Gb3 loss (% Gb3 loss = 100 - % Gb3-NBD signal) was used to 
plot the results. IC50 values were calculated using GraphPad  Prism 5 software.  
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Figure 1. Schematic representation of the DELOS-SUSP method for the preparation of GLA 
loaded liposome-RGD conjugates. The procedure includes: a) Loading of an organic solution 
of the lipidic membrane components (Cholesterol, DPPC and Cholesterol-PEG200-RGD) into 
an autoclave at a working temperature (Tw= 308 K) and atmospheric pressure. b) Addition of 
compressed CO2 to produce a CO2-expanded solution, at XCO2= 0.85, working pressure (Pw= 
10 MPa) and Tw, where all membrane components remain dissolved. c) Depressurization of 
the expanded solution over an aqueous solution containing the free GLA enzyme, in order to 
produce the nanoconjugates.  
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Figure 2. Cryo-TEM pictures showing the morphology of the nanoconjugates with different 
GLA concentrations. a) Unloaded liposomes-RGD, b) GLA loaded liposome-RGD conjugates 
containing 3 µg mL-1 of GLA, c) GLA loaded liposome-RGD conjugates containing 7 µg mL-
1 of GLA, d) GLA loaded liposome-RGD conjugates containing 16 µg mL-1 of GLA enzyme.  
Scale bars are 200 nm 
 
a b
c d
 31 
 
 
 
Figure 3. A) Ratio between the specific enzymatic activity of the GLA loaded 
nanoconjugates and of the free GLA in water for different enzyme concentrations. 
B) Evolution of the specific enzymatic activity of the free GLA, GLA loaded liposome-RGD 
conjugates plus non-loaded GLA (Total) and GLA loaded liposomes-RGD after the 
elimination of the non-loaded GLA by diafiltration, corresponding to the liposomal system 
with a GLA initial concentration of 8.5 µg mL-1 (see Table1). Samples were stored at 4 ºC 
during the time of analysis. Represented values correspond to mean ± SEM. 
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Figure 4. Results for the atomistic modeling of the interaction between GLA and a 
DPPC/Chol bilayer. The protein residues involved in the interaction with the membrane are 
shown as yellow bonds and the residues involved in the active enzymatic region are shown as 
red bonds.  Left: Equilibrium configuration of the protein dimer obtained from the 
approximate thermodynamic calculation. The boundary of the hypothetical membrane is 
shown in blue. Right: Snapshot of a particular configuration obtained in MD simulations of 
monomer and a DPPC/Chol bilayer. The lipids are shown as lines. The cholesterol molecules 
inside the membrane are emphasized. All images were produced using VMD.[48]  
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Figure 5. Internalization of nanovesicles on endothelial cells assessed by flow cytometry after 
30 and 180 minutes of incubation at 16 ºC and 37 ºC: A) Flow cytometry quantification of the 
fraction of cells that internalized plain liposomes and liposome-RGD conjugates as the 
percentage (%) of DiD-positive cells among the total number of cells. B) Mean fluorescence 
intensity (MFI) of DiD in the cells normalized to the maximum fluorescence intensity. Blue 
and green bars correspond to cells incubated at 16ºC and refer to the liposomes bound to the 
membrane but not internalized, since active internalization is inhibited at this temperature. 
Comparatively, yellow and red bars corresponding to cells incubated at 37ºC, have 
significantly higher values only in the case of RGD-containing liposomes, indicating that the 
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presence of the RGD moiety is essential for a fast and specific internalization of the 
liposomes.  
 
 
 
 
 
 
 
 
Figure 6. Confocal images of the cellular uptake of GLA-loaded liposome-RGD conjugates 
and unloaded liposome-RGD conjugates after 3 h incubation at 37 ºC. The arrows denote the 
sites of colocalization between the labeled conjugates and the lysosomes.  
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Figure 7. Effect of different formulations of GLA in the reduction of Gb3 deposits in aortic 
endothelial cells of Fabry KO mice. The activity of free GLA is compared to that of GLA 
loaded liposome-RGD conjugates containing non-loaded GLA (Total GLA), GLA loaded 
liposomes-RGD after the elimination of the non-loaded GLA (Loaded GLA), GLA adsorbed 
on the outside membrane of liposome-RGD (Liposome-RGD + Free GLA + Diafiltration), 
Loaded GLA mixed with additional free GLA (Loaded GLA + Free GLA) and Unloaded 
Liposome-RGD.  This last sample equals the concentration of lipids used for the Loaded GLA. 
For all the formulations it has been used the same GLA batch with an enzymatic activity of 
519 μmol h-1 mg-1. Represented values correspond to mean ± SEM value. 
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Table 1.  Physicochemical characteristics, entrapment efficiencies (EE) and loading of 
nanoliposome conjugates. The physicochemical characteristics of the conjugates after the 
separation of the non-loaded enzyme are given between brackets. 
 
Liposomal systems 
(Initial GLA 
concentration) 
Size ζ-
potential 
[mV] 
EE 
[%] 
GLA 
loadingc)     
[µg mg-1] 
GLA 
conc.d)  
[µg mL-1] 
 
Meana) [49] PdIb) GLA’s/lipe) 
GLA loaded 
liposomes-RGD  
(8.5 µg mL-1 ) 
168±1 
(146±1) 
0.33±0.01 
(0.29±0.03) 
18±1 
(-33±1) 39±10 (2.3±0.6) 
8.5 
(3±1) 1 
GLA loaded 
liposomes-RGD  
(20.0 µg mL-1) 
216±8 
(195±1) 
0.40±0.01 
(0.40±0.01) 
14±1 
(-24±2) 37±9 (5.8±1.3) 
20 
(7±2) 3 
GLA loaded 
liposomes-RGD  
(42.5 µg mL-1 ) 
226±3 
(215± 
6) 
0.45±0.04 
(0.33±0.02) 
9.8±0.4 
(-32±1) 38±8 (11.3±2.3) 
42.5 
(16±3) 4 
Liposomes-
RGD/water (blank) 
160±1 0.38±0.02 30±2 - - - - 
Plain liposomes 
(without RGD) 
149±2 0.20±0.01 3.5±0.2 - - - - 
GLA loaded plain 
liposomes  
(20 µg mL-1) 
158±3 
(182± 
4) 
0.18±0.01 
(0.40±0.01) 
5.97±0.09 
(-
12.7±0.3) 
33±11 (4.6±1.5) 20 (7±2) 3 
 
a) Intensity weighted mean hydrodynamic size (diameter) measured by dynamic light scattering; 
b)Polidispersity index showing the width of the particle size distribution; c) Mass of the integrated 
enzyme (determined by Western-blot), divided by the total mass of the membrane components forming 
the vesicles; d) Mass of enzyme present divided by the volume of the vesicular suspension. 
Error margins are SD; e) Number of GLA molecules per nanoliposome. 
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Table 2. Specific enzymatic activities (in µmol 4-MU mg-1 GLA h-1) of GLA liposomal 
systems. 
 
Liposomal systems  
(Initial GLA concentration) Total
a) GLA loaded liposomesb) Free GLA in waterc) 
GLA loaded liposomes-RGD 
(8.5 µg mL-1) 913 ± 27 924 ± 89 304 ± 14 
GLA loaded liposomes-RGD 
(20 µg mL-1) 846 ± 270 1253 ± 65 400 ± 49 
GLA loaded liposomes-RGD 
(42.5 µg mL-1) 879 ± 140 705 ± 88 548 ± 200 
Unloaded Liposomes-RGD 
 0 0 0 
 a) Total GLA, corresponding to the fraction prior diafiltration in which the non-loaded and the 
liposome loaded GLA coexist together; b) GLA loaded nanoliposomes, corresponding to the fraction 
obtained after the diafiltration process; c) free GLA, corresponding  to  the initial GLA aqueous 
solution before its conjugation. Error margins are SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
